Aims: The metastasis suppressor gene, N-myc downstream regulated gene-1 (NDRG1), is negatively correlated with tumor progression in multiple neoplasms, including pancreatic cancer. Moreover, NDRG1 is an iron-regulated gene that is markedly upregulated by cellular iron-depletion using novel antitumor agents such as the chelator, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), in pancreatic cancer cells. However, the exact function(s) of NDRG1 remain to be established and are important to elucidate. Results: In the current study, using gene-array analysis along with NDRG1 overexpression and silencing, we identified the molecular targets of NDRG1 in three pancreatic cancer cell lines. We demonstrate that NDRG1 upregulates neural precursor cell expressed developmentally downregulated 4-like (NEDD4L) and GLI-similar-3 (GLIS3). Further studies examining the downstream effects of NEDD4L led to the discovery that NDRG1 affects the transforming growth factor-β (TGF-β) pathway, leading to the upregulation of two key tumor suppressor proteins, namely phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and mothers against decapentaplegic homolog-4 (SMAD4). Moreover, NDRG1 inhibited the phosphatidylinositol 3-kinase (PI3K) and Ras oncogenic pathways. Innovation: This study provides significant insights into the mechanisms underlying the antitumor activity of NDRG1. For the first time, a role for NDRG1 is established in regulating the key signaling pathways involved in oncogenesis (TGF-β, PI3K, and Ras pathways). Conclusion: The identified target genes of NDRG1 and their effect on the TGF-β signaling pathway reveal its molecular function in pancreatic cancer and a novel therapeutic avenue. Antioxid. Redox Signal. 00, 000–000.
Get full access to this article
View all access options for this article.
References
1.
AngstE, SiboldS, TiffonC, WeimannR, GloorB, CandinasD, StrokaD. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer, 95:307–313. 2006.
2.
BandyopadhyayS, PaiSK, GrossSC, HirotaS, HosobeS, MiuraK, SaitoK, CommesT, HayashiS, WatabeM, WatabeK. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res, 63:1731–1736. 2003.
3.
BandyopadhyayS, PaiSK, HirotaS, HosobeS, TakanoY, SaitoK, PiquemalD, CommesT, WatabeM, GrossSC, WangY, RanS, WatabeK. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene, 23:5675–5681. 2004.
4.
BurrisH3rd, Rocha-LimaC. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist, 13:289–298. 2008.
5.
ChalhoubN, BakerSJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol, 4:127–150. 2009.
6.
ChenH, RossCA, WangN, HuoY, MacKinnonDF, PotashJB, SimpsonSG, McMahonFJ, DePauloJRJr., McInnisMG. NEDD4L on human chromosome 18q21 has multiple forms of transcripts and is a homologue of the mouse Nedd4-2 gene. Eur J Hum Genet, 9:922–930. 2001.
7.
ChengJQ, RuggeriB, KleinWM, SonodaG, AltomareDA, WatsonDK, TestaJR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A, 93:3636–3641. 1996.
8.
ChowJY, BanM, WuHL, NguyenF, HuangM, ChungH, DongH, CarethersJM. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol, 298:G275–G282. 2010.
9.
ChowJY, CabralJA, ChangJ, CarethersJM. TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer Biol Ther, 7:1694–1699. 2008.
10.
ChowJY, DongH, QuachKT, Van NguyenPN, ChenK, CarethersJM. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol, 294:G899–G905. 2008.
11.
ChowJY, QuachKT, CabreraBL, CabralJA, BeckSE, CarethersJM. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis, 28:2321–2327. 2007.
12.
DongZ, ArnoldRJ, YangY, ParkMH, HrncirovaP, MechrefY, NovotnyMV, ZhangJT. Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis. Mol Cell Proteomics, 4:993–1001. 2005.
13.
EllenT, KeQ, ZhangP, CostaM. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis, 29:2–8. 2007.
14.
EllenriederV. TGFbeta regulated gene expression by Smads and Sp1/KLF-like transcription factors in cancer. Anticancer Res, 28:1531–1539. 2008.
GeissmannF, ProstC, MonnetJP, DyM, BrousseN, HermineO. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med, 187:961–966. 1998.
17.
GysinS, RickertP, KasturyK, McMahonM. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer, 44:37–51. 2005.
18.
HahnSA, HoqueAT, MoskalukCA, da CostaLT, SchutteM, RozenblumE, SeymourAB, WeinsteinCL, YeoCJ, HrubanRH, KernSE. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res, 56:490–494. 1996.
19.
HahnSA, SchutteM, HoqueAT, MoskalukCA, da CostaLT, RozenblumE, WeinsteinCL, FischerA, YeoCJ, HrubanRH, KernSE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271:350–353. 1996.
20.
HeJ, de la MonteS, WandsJR. The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun, 397:513–519. 2010.
21.
HolmS. A simple sequentially rejective multiple test procedure. Scand J Stat, 6:65–70. 1979.
22.
HosoiF, IzumiH, KawaharaA, MurakamiY, KinoshitaH, KageM, NishioK, KohnoK, KuwanoM, OnoM. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. Cancer Res, 69:4983–4991. 2009.
23.
HuXY, XuYM, FuQ, YuJJ, HuangJ. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. Eur J Surg Oncol, 35:527–531. 2009.
24.
InghamRJ, GishG, PawsonT. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene, 23:1972–1984. 2004.
25.
JiangBH, LiuLZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res, 102:19–65. 2009.
26.
KimYS, NakanishiG, LewandoskiM, JettenAM. GLIS3, a novel member of the GLIS subfamily of Kruppel-like zinc finger proteins with repressor and activation functions. Nucleic Acids Res, 31:5513–5525. 2003.
27.
KovacevicZ, ChikhaniS, LovejoyDB, RichardsonDR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor, NDRG1: A new strategy for the treatment of pancreatic cancer. Mol Pharmacol, 80:598–609. 2011.
28.
KovacevicZ, RichardsonDR. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 6:1982–1994. 2006.
KretzschmarM, DoodyJ, TimokhinaI, MassagueJ. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev, 13:804–816. 1999.
31.
LachatP, ShawP, GebhardS, van BelzenN, ChaubertP, BosmanFT. Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol, 118:399–408. 2002.
32.
LaghiL, OrbetegliO, BianchiP, ZerbiA, Di CarloV, BolandCR, MalesciA. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene, 21:4301–4306. 2002.
33.
LeNT, RichardsonDR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood, 104:2967–2975. 2004.
34.
LevyL, HillCS. Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol, 25:8108–8125. 2005.
35.
MaehamaT, DixonJE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 273:13375–13378. 1998.
36.
MaruyamaY, OnoM, KawaharaA, YokoyamaT, BasakiY, KageM, AoyagiS, KinoshitaH, KuwanoM. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res, 66:6233–6242. 2006.
37.
MassagueJ. TGF-beta signal transduction. Annu Rev Biochem, 67:753–791. 1998.
38.
MurakamiY, HosoiF, IzumiH, MaruyamaY, UreshinoH, WatariK, KohnoK, KuwanoM, OnoM. Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem Biophys Res Commun, 396:376–381. 2010.
39.
MurrayJT, CampbellDG, MorriceN, AuldGC, ShpiroN, MarquezR, PeggieM, BainJ, BloombergGB, GrahammerF, LangF, WulffP, KuhlD, CohenP. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J, 384:477–488. 2004.
40.
SimeoneDM, PhamT, LogsdonCD. Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann Surg, 232:73–80. 2000.
41.
SmythGK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 3,Article32004.
42.
StathopoulosGP, AndroulakisN, SouglakosJ, StathopoulosJ, GeorgouliasV. Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res, 28:1303–1308. 2008.
43.
SteelmanLS, StadelmanKM, ChappellWH, HornS, BaseckeJ, CervelloM, NicolettiF, LibraM, StivalaF, MartelliAM, McCubreyJA. Akt as a therapeutic target in cancer. Expert Opin Ther Targets, 12:1139–1165. 2008.
44.
SubramanianG, SchwarzRE, HigginsL, McEnroeG, ChakravartyS, DugarS, ReissM. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res, 64:5200–5211. 2004.
45.
TaplickJ, KurtevV, KrobothK, PoschM, LechnerT, SeiserC. Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J Mol Biol, 308:27–38. 2001.
46.
VenkatasubbaraoK, AhmedMM, MohiuddinM, SwiderskiC, LeeE, GowerWRJr., SalhabKF, McGrathP, StrodelW, FreemanJW. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res, 20:43–51. 2000.
47.
WhitnallM, HowardJ, PonkaP, RichardsonDR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A, 103:14901–14906. 2006.
48.
YangG, YangX. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci, 6:1–8. 2010.
49.
YangY, ZhouF, FangZ, WangL, LiZ, SunL, WangC, YaoW, CaiX, JinJ, ZhaX. Post-transcriptional and post-translational regulation of PTEN by transforming growth factor-beta1. J Cell Biochem, 106:1102–1112. 2009.
50.
YuY, KovacevicZ, RichardsonDR. Tuning cell cycle regulation with an iron key. Cell Cycle, 6:1982–1994. 2007.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
